SCHEMBL4969288

SCHEMBL4969288

O=C(C=Cc1ccc(O)c(O)c1)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
MEN1 O00255 3/20 0.53
GAA P10253 3/20 0.53
KMT2A Q03164 3/20 0.53
KDM4E B2RXH2 2/20 0.53
HSD17B10 Q99714 2/20 0.53
ALDH1A1 P00352 2/20 0.53
LMNA P02545 2/20 0.53
POLB P06746 2/20 0.53
TTR P02766 2/20 0.53
APP P05067 2/20 0.53
HDAC3 O15379 2/20 0.53
HDAC4 P56524 2/20 0.53
HDAC7 Q8WUI4 2/20 0.53
HDAC2 Q92769 2/20 0.53
HDAC11 Q96DB2 2/20 0.53
HDAC8 Q9BY41 2/20 0.53
HDAC6 Q9UBN7 2/20 0.53
HDAC9 Q9UKV0 2/20 0.53
HDAC5 Q9UQL6 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4969284 1.00 MAPT (0.53) MAPTMEN1GAAKMT2AKDM4E
SCHEMBL14523871 0.79 ELANE (0.45) MAPTMEN1GAAKMT2AKDM4E
SCHEMBL14416833 0.79 ALDH1A1 (0.46) MAPTMEN1GAAKMT2AKDM4E
SCHEMBL4776395 0.79 ALDH1A1 (0.63) MAPTMEN1GAAKMT2AKDM4E
SCHEMBL4971211 0.79 ALDH1A1 (0.46) MAPTMEN1GAAKMT2AKDM4E
SCHEMBL4776401 0.79 ALDH1A1 (0.63) MAPTMEN1GAAKMT2AKDM4E
SCHEMBL4971206 0.79 ALDH1A1 (0.46) MAPTMEN1GAAKMT2AKDM4E
SCHEMBL18317450 0.79 ALDH1A1 (0.45) MAPTMEN1GAAKMT2AALDH1A1
SCHEMBL8876584 0.79 HSD11B1 (0.51) MAPTMEN1GAAKMT2AALDH1A1
SCHEMBL6092094 0.79 HSD11B1 (0.51) MAPTMEN1GAAKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 US claimed
EP-1623704-A1 THERAPEUTIC AGENT TAKARA BIO INC. (JP) 2006-02-08 EP claimed
EP-1254658-B1 REMEDIES FOR THE TREATMENT OF NERVE DIORDERS TAKARA BIO INC (JP) 2008-09-24 EP disclosed
US-7268160-B2 Remedies TAKARA BIO, INC. (JP) 2007-09-11 US disclosed
US-20070092551-A1 Therapeutic agent TAKARA BIO INC. (JP) 2007-04-26 US disclosed
EP-1623704-A1 THERAPEUTIC AGENT TAKARA BIO INC. (JP) 2006-02-08 EP disclosed
US-20030144316-A1 Remedies TAKARA BIO INC. (JP) 2003-07-31 US disclosed
EP-1254658-A1 REMEDIES TAKARA BIO INC. (JP) 2002-11-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144316-A1 Remedies NGF, BDNF, NTRK2 MAPT 1407/4885MEN1 523/4885GAA 570/4885
US-20070092551-A1 Therapeutic agent FABP4, GPR119, IAPP MAPT 2256/4885MEN1 2467/4885GAA 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.